Ocata Therapeutics Company Profile (NASDAQ:OCAT)

About Ocata Therapeutics (NASDAQ:OCAT)

Ocata Therapeutics logoOcata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OCAT
  • CUSIP: N/A
  • Web: www.ocata.com
Average Prices:
  • 50 Day Moving Avg: $8.00
  • 200 Day Moving Avg: $6.00
  • 52 Week Range: $3.06 - $8.71
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.29
  • P/E Growth: 0
  • Net Margins: -4,564.66%
  • Return on Equity: -103.02%
  • Return on Assets: -46.18%
  • Average Volume: 830,858 shs.

Frequently Asked Questions for Ocata Therapeutics (NASDAQ:OCAT)

What is Ocata Therapeutics' stock symbol?

Ocata Therapeutics trades on the NASDAQ under the ticker symbol "OCAT."

How were Ocata Therapeutics' earnings last quarter?

Ocata Therapeutics Inc (NASDAQ:OCAT) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.01. The firm had revenue of $0.04 million for the quarter. Ocata Therapeutics had a negative return on equity of 103.02% and a negative net margin of 4,564.66%. View Ocata Therapeutics' Earnings History.

Who are some of Ocata Therapeutics' key competitors?

How do I buy Ocata Therapeutics stock?

Shares of Ocata Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocata Therapeutics' stock price today?

One share of Ocata Therapeutics stock can currently be purchased for approximately $8.47.

MarketBeat Community Rating for Ocata Therapeutics (NASDAQ OCAT)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  74
MarketBeat's community ratings are surveys of what our community members think about Ocata Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ocata Therapeutics (NASDAQ:OCAT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Ocata Therapeutics (NASDAQ:OCAT)
Price Target History for Ocata Therapeutics (NASDAQ:OCAT)
Analysts' Ratings History for Ocata Therapeutics (NASDAQ:OCAT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/23/2016Cantor FitzgeraldReiterated RatingHold$8.50N/AView Rating Details
11/10/2015Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Ocata Therapeutics (NASDAQ:OCAT)
Earnings by Quarter for Ocata Therapeutics (NASDAQ:OCAT)
Earnings History by Quarter for Ocata Therapeutics (NASDAQ OCAT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2015Q215($0.19)($0.20)$0.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ocata Therapeutics (NASDAQ:OCAT)
Current Year EPS Consensus Estimate: $-0.60 EPS
Next Year EPS Consensus Estimate: $-0.49 EPS


Dividend History for Ocata Therapeutics (NASDAQ:OCAT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ocata Therapeutics (NASDAQ:OCAT)
Insider Trades by Quarter for Ocata Therapeutics (NASDAQ:OCAT)
Institutional Ownership by Quarter for Ocata Therapeutics (NASDAQ:OCAT)
Insider Trades by Quarter for Ocata Therapeutics (NASDAQ:OCAT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2015Robert LanzainsiderSell35,000$8.31$290,850.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ocata Therapeutics (NASDAQ:OCAT)
Latest Headlines for Ocata Therapeutics (NASDAQ:OCAT)
bizjournals.com logoHow Flagship's newest startup is pursuing a 'holy grail' of biotech - Boston Business Journal
www.bizjournals.com - June 23 at 8:42 AM
prnewswire.com logoFlagship Pioneering Launches Sigilon Therapeutics to Advance Afibromer™ Encapsulated Cell Therapies - PR Newswire (press release)
www.prnewswire.com - June 22 at 6:08 AM
bizjournals.com logoGlobal Regenerative Medicine Market Analysis & Forecast 2017-2021 - Research and Markets
www.bizjournals.com - May 5 at 7:14 PM
bloomberg.com logoPharma CEO Hunts New Trophy After Prostate Cancer Blockbuster ... - Bloomberg
www.bloomberg.com - December 1 at 12:08 AM
bloomberg.com logoPharma CEO Hunts New Trophy After Prostate Cancer Blockbuster
www.bloomberg.com - November 30 at 11:50 AM
businesswire.com logoBioTime Co-CEO Dr. Michael D. West to Chair Cell Therapy Track at World Precision Medicine Congress USA 2016 - Business Wire (press release)
www.businesswire.com - November 10 at 6:24 PM
thestreet.com logoApplied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen - TheStreet.com
www.thestreet.com - September 20 at 11:49 AM
bizjournals.com logoChinese biotech Vcanbio opens first U.S. subsidiaries in Natick - Boston Business Journal (blog)
www.bizjournals.com - September 13 at 11:24 AM
bizjournals.com logoPharma Leader Series: Top Stem Cell Companies Report 2016-2026: Market Analysis and Leading Players in the United States, Europe, Israel and Asia
www.bizjournals.com - September 6 at 11:18 AM
bloomberg.com logoKey Executives for Ocata Therapeutics, Inc.
www.bloomberg.com - August 23 at 6:47 PM
seekingalpha.com logoOcata Shareholder Majority Rejects Astellas Offer As Woefully Inadequate - Seeking Alpha
seekingalpha.com - January 26 at 2:31 PM



Ocata Therapeutics (OCAT) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.